The use of autologous mesenchymal stem cells in complications of diabetes mellitus, in particular diabetic retinopathy: inputs and insights
Yeltokova M. Akhmedyanova Z. Bayanbayeva Z. Khassenova A. Yermekova K.
2022National Scientific Medical Center
Journal of Clinical Medicine of Kazakhstan
2022#19Issue 29 - 13 pp.
The review provided reveals the analysis of the available scientific literature on the feasibility of using cellular technologies, such as, autologous mesenchymal stem cells (MSCs) for diabetic retinopathy treatment. The results indicated the viability of cellular technologies in clinical ophthalmology with respect to anatomical features and immune privilege of the organ of vision. Additionally, feasibility, safety, and optimization of pathogenetic therapy for MSC transplantation expands the prospect of their use in late complications of type 1 and type 2 diabetes mellitus, in particular, diabetic retinopathy.
diabetic retinopathy , mesenchymal stem cells
Text of the article Перейти на текст статьи
Department of Ophthalmology, National Scientific Medical Center, Astana, Kazakhstan
Department of Eye Diseases, Astana Medical University, Astana, Kazakhstan
Department of Academic Quality Unit, School of Public Health, Asfendiyarov Kazakh National Medical University, Almaty, Kazakhstan
Department of Ophthalmology
Department of Eye Diseases
Department of Academic Quality Unit
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026